Literature DB >> 9686372

Disturbed metabolism of guanidino compounds characterized by elevated excretion of beta-guanidinopropionic acid and gamma-guanidinobutyric acid--an effect of vigabatrin treatment?

A Schulze1, E Mayatepek, S Frank, B Marescau, P P De Deyn, P Bachert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9686372     DOI： 10.1023/a:1005376307471

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN： 0141-8955            Impact factor:   4.982


× No keyword cloud information.
  7 in total

1.  Guanidino compounds in serum, urine, liver, kidney, and brain of man and some ureotelic animals.

Authors:  B Marescau; D R Deshmukh; M Kockx; I Possemiers; I A Qureshi; P Wiechert; P P De Deyn
Journal:  Metabolism       Date:  1992-05       Impact factor: 8.694

2.  Creatine deficiency syndrome caused by guanidinoacetate methyltransferase deficiency: diagnostic tools for a new inborn error of metabolism.

Authors:  A Schulze; T Hess; R Wevers; E Mayatepek; P Bachert; B Marescau; M V Knopp; P P De Deyn; H J Bremer; D Rating
Journal:  J Pediatr       Date:  1997-10       Impact factor: 4.406

3.  Guanidino compound analysis as a complementary diagnostic parameter for hyperargininemia: follow-up of guanidino compound levels during therapy.

Authors:  B Marescau; P P De Deyn; A Lowenthal; I A Qureshi; I Antonozzi; C Bachmann; S D Cederbaum; R Cerone; N Chamoles; J P Colombo
Journal:  Pediatr Res       Date:  1990-03       Impact factor: 3.756

4.  gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice.

Authors:  M J Jung; B Lippert; B W Metcalf; P Böhlen; P J Schechter
Journal:  J Neurochem       Date:  1977-11       Impact factor: 5.372

5.  Guanidino compounds in serum and cerebrospinal fluid of non-dialyzed patients with renal insufficiency.

Authors:  P P De Deyn; B Marescau; J J Cuykens; L Van Gorp; A Lowenthal; W P De Potter
Journal:  Clin Chim Acta       Date:  1987-07-30       Impact factor: 3.786

6.  Convulsive action and toxicity of uremic guanidino compounds: behavioral assessment and relation to brain concentration in adult mice.

Authors:  R D'Hooge; Y Q Pei; B Marescau; P P De Deyn
Journal:  J Neurol Sci       Date:  1992-10       Impact factor: 3.181

7.  Guanidino compound metabolism in rats subjected to 20% to 90% nephrectomy.

Authors:  O Levillain; B Marescau; P P de Deyn
Journal:  Kidney Int       Date:  1995-02       Impact factor: 10.612
  7 in total
  4 in total

Review 1.  Succinic semialdehyde dehydrogenase: biochemical-molecular-clinical disease mechanisms, redox regulation, and functional significance.

Authors:  Kyung-Jin Kim; Phillip L Pearl; Kimmo Jensen; O Carter Snead; Patrizia Malaspina; Cornelis Jakobs; K Michael Gibson
Journal:  Antioxid Redox Signal       Date:  2011-04-10       Impact factor: 8.401

2.  Behavioral metabolomics analysis identifies novel neurochemical signatures in methamphetamine sensitization.

Authors:  D E Adkins; J L McClay; S A Vunck; A M Batman; R E Vann; S L Clark; R P Souza; J J Crowley; P F Sullivan; E J C G van den Oord; P M Beardsley
Journal:  Genes Brain Behav       Date:  2013-09-30       Impact factor: 3.449

3.  Preclinical tissue distribution and metabolic correlations of vigabatrin, an antiepileptic drug associated with potential use-limiting visual field defects.

Authors:  Dana C Walters; Erwin E W Jansen; Garrett R Ainslie; Gajja S Salomons; Madalyn N Brown; Michelle A Schmidt; Jean-Baptiste Roullet; K M Gibson
Journal:  Pharmacol Res Perspect       Date:  2019-01-07

4.  Neurotransmitter alterations in embryonic succinate semialdehyde dehydrogenase (SSADH) deficiency suggest a heightened excitatory state during development.

Authors:  Erwin E W Jansen; Eduard Struys; Cornelis Jakobs; Elizabeth Hager; O Carter Snead; K Michael Gibson
Journal:  BMC Dev Biol       Date:  2008-11-28       Impact factor: 1.978
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.